One Enzyme Might Control Tissue Aging

Why It Matters

Targeting 15‑PGDH offers a potentially universal anti‑aging strategy and could provide the first stem‑cell‑independent treatment for cartilage degeneration, a major unmet medical need.

Key Takeaways

• 15‑PGDH enzyme rises with age, depleting repair‑boosting PGE2.
• Inhibiting 15‑PGDH rejuvenates muscle, bone, nerve, colon, liver.
• Cartilage lacks stem cells, testing enzyme blockade there is critical.
• Blocking 15‑PGDH restores PGE2, reactivating tissue repair pathways.
• Success in cartilage could reveal a stem‑cell‑independent rejuvenation mechanism.

Summary

Blouse Lab has coined the term “gerro enzyme” for proteins that accumulate with age and drive tissue decline. Their current focus is 15‑hydroxyprostaglandin dehydrogenase (15‑PGDH), an enzyme that degrades prostaglandin E2 (PGE2), a molecule essential for tissue repair.

The hypothesis is straightforward: aging tissues overexpress 15‑PGDH, which lowers PGE2 levels and stalls regeneration. By pharmacologically inhibiting 15‑PGDH, PGE2 is restored, re‑engaging repair pathways. Pre‑clinical studies have shown that this approach rejuvenates muscle, bone, nerve, colon, liver, and blood.

The team highlights that cartilage—an avascular tissue without resident stem cells—has not yet been examined. Demonstrating efficacy in cartilage would suggest a mechanism that does not rely on stem‑cell activation, distinguishing it from the other organs tested.

If 15‑PGDH blockade can revive cartilage, it could open a new therapeutic class for osteoarthritis and broader age‑related degeneration, positioning the enzyme as a universal target for systemic rejuvenation.

Original Description

As you age, this enzyme builds up…

and shuts down your body’s ability to repair itself.

No repair signal.

No healing.

Block the enzyme →

repair comes back.

Same cells.

Better function.

If this works in cartilage…

it changes everything.